Phathom Pharmaceuticals (PHAT) Other Non-Current Assets (2019 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Other Non-Current Assets of $3.1 million for Q2 2026, up 7.9% year-over-year from $2.9 million in Q2 2025, and little changed quarter-over-quarter from $3.1 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Other Non-Current Assets for 8 consecutive years, with $3.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Assets rose 7.9% year-over-year to $3.1 million; the TTM figure through Jun 2026 stood at $3.1 million (up 7.9% YoY), while the FY2025 annual figure was $2.9 million, up 1.92% from the prior year.
- Other Non-Current Assets held at $3.1 million in Q2 2026 per PHAT's latest filing, from $3.1 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $3.8 million in Q3 2023 and bottomed at $505000.0 in Q4 2022.
- Historically, Other Non-Current Assets has averaged $2.4 million across 5 years, with a median of $2.9 million in 2024.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets sank 37.27% — and 2024, when it jumped 467.72%.
- Phathom Pharmaceuticals' Other Non-Current Assets stood at $505000.0 in 2022, then surged by 466.93% to $2.9 million in 2023, then retreated by 0.03% to $2.9 million in 2024, then gained by 1.92% to $2.9 million in 2025, then climbed by 5.86% to $3.1 million in 2026.
- Business Quant data shows PHAT's Other Non-Current Assets at $3.1 million in Q2 2026, $3.1 million in Q1 2026, and $2.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | 3.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.09 Mn |
| Mar 31, 2026 | 2.86 Mn |
| Dec 31, 2025 | 2.86 Mn |
| Sep 30, 2025 | 2.86 Mn |
| Jun 30, 2025 | 2.86 Mn |
| Mar 31, 2025 | 2.86 Mn |
| Dec 31, 2024 | 2.86 Mn |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 2.86 Mn |
| Mar 31, 2024 | 2.87 Mn |
| Dec 31, 2023 | 1.69 Mn |
| Sep 30, 2023 | 3.75 Mn |
| Jun 30, 2023 | 528,000.00 |
| Mar 31, 2023 | 299,000.00 |
| Dec 31, 2022 | 299,000.00 |
| Sep 30, 2022 | 805,000.00 |
| Jun 30, 2022 | 805,000.00 |
| Mar 31, 2022 | 805,000.00 |
| Dec 31, 2021 | 160,000.00 |
| Sep 30, 2021 | 341,000.00 |